Clinical Features of Dermatomyositis/Polymyositis with Anti-MDA5 Antibody Positivity

Table 5

Prognosis analysis of 18 patients with positive anti-MDA5 antibodies with different treatment modalities (n (%)).

Treatment modality	Survival (n = 15)	Death (n = 3)	χ ^2	P
Treatment 1	6 (40.0)	2 (66.7)	2.000	0.157
Treatment 2	9 (60.0)	1 (33.3)	6.400	0.011
Treatment 3	0	0	—	—

Note. Chi-square test; Treatment 1: methylprednisolone ≥ 60 mg/d + immunosuppression; Treatment 2: methylprednisolone < 60 mg/d (or oral equivalent prednisone) + immunosuppression; Treatment 3: hormones only without combined immunosuppression.